ENDPOINTS

Nuvation Bio’s $250M funding; Leqembi rejected again in Australia

Plus, news about IN8bio and Syros: Nuvation Bio’s new funding: The New York biotech will get $150 million in royalty interest financing and up to $100 million ...

Mar 3, 2025 - 16:47
 0
Nuvation Bio’s $250M funding; Leqembi rejected again in Australia
Plus, news about IN8bio and Syros: Nuvation Bio’s new funding: The New York biotech will get $150 million in royalty interest financing and up to $100 million ...
Read More

Tags:

Previous Article

Anker’s fully waterproof Bluetooth speaker is just $21 right now

Next Article

The power of passive investors is a double-edged sword, experts argue

Related Posts

Trump’s HHS defends drug price negotiations in Novartis suit

Trump’s HHS defends drug price negotiations in Novartis...

Feb 20, 2025  0

Trump’s science crackdown hits rare disease medicine: ‘We need to sit down with Elon Musk’

Trump’s science crackdown hits rare disease medicine: ‘...

Feb 28, 2025  0

After research pivot, Biogen beefs up pipeline with Stoke's late-stage Dravet candidate

After research pivot, Biogen beefs up pipeline with Sto...

Feb 18, 2025  0